BrECADD raises the bar in classical Hodgkin lymphoma

IF 81.1 1区 医学 Q1 ONCOLOGY
David Killock
{"title":"BrECADD raises the bar in classical Hodgkin lymphoma","authors":"David Killock","doi":"10.1038/s41571-024-00928-5","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":19079,"journal":{"name":"Nature Reviews Clinical Oncology","volume":"21 9","pages":"639-639"},"PeriodicalIF":81.1000,"publicationDate":"2024-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nature Reviews Clinical Oncology","FirstCategoryId":"3","ListUrlMain":"https://www.nature.com/articles/s41571-024-00928-5","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
BrECADD 提高了经典霍奇金淋巴瘤的治疗标准
eBEACOPP 方案包括博来霉素、长春新碱、丙卡巴嗪和泼尼松,以及递增剂量的依托泊苷、多柔比星和环磷酰胺,是治疗传统霍奇金淋巴瘤(cHL)的标准一线疗法。这种强化治疗方案的初治率最高,但同时也带来了大量且往往是持续性的治疗相关病症。现在,HD21 试验的数据表明,由抗体药物共轭物布伦妥昔单抗维多汀加依托泊苷、环磷酰胺、多柔比星、达卡巴嗪和地塞米松(BrECADD)组成的新方案的风险收益比得到了改善。在这项III期试验中,1500名18-60岁的晚期cHL患者被随机分配(1:1)接受BrECADD与eBEACOPP的PET指导治疗,如果PET-2阴性(第2周期后多维尔评分为1-3),则各治疗4个周期;如果PET-2阳性(多维尔评分为4-5),则各治疗6个周期。共同主要终点是耐受性的改善(由研究者评估的治疗相关发病率(急性4级血液学毒性或3-4级非血液学器官系统毒性)定义)和非劣效无进展生存期(PFS)。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
99.40
自引率
0.40%
发文量
114
审稿时长
6-12 weeks
期刊介绍: Nature Reviews publishes clinical content authored by internationally renowned clinical academics and researchers, catering to readers in the medical sciences at postgraduate levels and beyond. Although targeted at practicing doctors, researchers, and academics within specific specialties, the aim is to ensure accessibility for readers across various medical disciplines. The journal features in-depth Reviews offering authoritative and current information, contextualizing topics within the history and development of a field. Perspectives, News & Views articles, and the Research Highlights section provide topical discussions, opinions, and filtered primary research from diverse medical journals.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信